This agreement covers all European territories, reinforcing the two companies’ position as leading providers of scientifically supported probiotics for women’s health. The strain, originally licensed from Proge Farm to Lallemand for Asia, the Americas, France, and the Czech Republic under the first agreement signed on June 30, 2020, is now available as Lactiplantibacillus plantarum P17630 in Europe, also inside Lallemand’s blends.
Mirabel, Canada, December 12, 2025 – “This achievement reflects the strong market adoption and trust in Lactiplantibacillus plantarum PROGE P17630 as a natural solution for women’s intimate health. Expanding our licensing rights worldwide allows us to deliver this unique strain to more women seeking effective, convenient oral probiotics” said Isabelle Champié, Vice President Sales and Marketing at Lallemand Health Solutions.
Novara, Italy, December 12, 2025 – “We are proud to strengthen our collaboration with Lallemand Health Solutions, a global leader in probiotics. Following the registration in Europe of our Live Biotherapeutic Product for vaginal use based on our Lactiplantibacillus plantarum P17630, this agreement reinforces the possibility for our strain to reach women everywhere also for oral administration, improving quality of life through science-backed solutions” added Giancarla Dondi, CEO of Proge Farm.
Global leadership in women’s health probiotics
With this new agreement, Proge Farm and Lallemand Health Solutions strengthen their leadership in the women’s health probiotics segment, a fast-growing niche driven by consumer demand for natural, effective solutions for intimate health. Proge Farm and Lallemand share the same approach, combining scientific rigour, regulatory expertise, and global reach to deliver premium probiotic solutions that improve women’s quality of life.
Marketing and health Canada recognition
Lactiplantibacillus plantarum PROGE P17630 (Rosella), offers women a convenient oral solution for intimate health. In September 2021, Health Canada officially recognised the strain’s benefits, granting claims such as:
- Helps support female or vaginal health
- Maintains a healthy vaginal microbiome
- This recognition confirms the strain’s strong scientific foundation and global credibility, reinforcing its role as a trusted solution for women’s health.
About Lactiplantibacillus plantarum PROGE P17630 for oral use
- Isolated from healthy vaginal flora
- Supported by six clinical studies involving over 800 women, including oral administration
- Demonstrated benefits for maintaining vaginal balance and supporting conventional treatments for recurrent vulvovaginal candidiasis (rVVC)
- Convenient oral dosage: 5B CFU/day
